Document is current

Article History

Received: 19 January 2024

Accepted: 29 July 2024

First Online: 15 August 2024

Declarations

:

: Approval was granted by the Ethics Committee of Charité – Universitätsmedizin Berlin (Date of vote: 2017-07-06; Ethic committee number EA1/066/17). All study participants are informed comprehensively and with sufficient time for them to reflect on the nature and scope of the study. Written informed consent is obtained from all participants prior to all study-related procedures. Informed consent to participate includes permission to analyse data and samples and to publish all results, at least by the BeLOVE Group. BeLOVE was registered at the approved WHO primary register: German Clinical Trials Register: ; WHO International Clinical Registry Platform: .

: Frank Edelmann (FE) reports grants from German Research Foundation (DFG), grants from German Ministry of Education and Research, grants from the German Herta Foundation; during the conduct of the study; personal fees and non-financial support from Novartis, grants and personal fees from Boehringer Ingelheim, personal fees from CVRx, Pfizer, Medtronic, grants and personal fees from Servier, personal fees from MSD, personal fees from Merck & Co., grants from AstraZeneca, personal fees from Bayer, personal fees from Resmed, personal fees from Berlin Chemie, grants from Thermo Fischer, personal fees from Vifor Pharma, personal fees from PharmaCosmos outside the submitted work.Matthias Endres (ME) reports grants from Bayer and fees paid to the Charité from Abbot, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Amgen, Sanofi, , Novartis, Pfizer, all outside the submitted work. ME received funding from DFG under Germany´s Excellence Strategy – EXC-2049 – 390688087, Collaborative Research Center ReTune TRR 295- 424778381, BMBF, DZNE, DZHK, EU, Corona Foundation, and Fondation Leducq.Holger Gerhardt (HG) reports grants from the DFG, the Leducq Foundation, the BMBF and the German Center for Cardiovascular Research (DZHK) during the conduct of the study, outside of the submitted work.Ulf Landmesser (UL) reports research funding from German Cardiovascular Research Network (DZHK); Fondation Leducq; research grants from Novartis, Bayer and AmgenKnut Mai (KM) declares that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.Gregor Liegl (GL), received funding for research from the German Research Foundation (DFG).Dominik N. Müller (DNM) received funding for research from Bayer Healthcare, Deutsche Forschungsgemeinschaft and from BMBF.Christian H Nolte (CHN) received research grants from German Ministry of Research and Education, German Center for neurodegenerative Diseases (DZNE), German Center for cardiovascular Research (DZHK), and speaker and/or consultation fees from Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer Pharma, Abbott, Novartis, Daichii-Sankyo and Alexion all outside the submitted work.Tobias Pischon (TP) received grants from the Federal Ministry of Education and Research (BMBF), the Federal Ministry of Food and Agriculture (BMEL), the Federal Ministry for Economic Affairs and Energy (BMWi), the Deutsche Forschungsgemeinschaft (DFG), Deutsche Herzstiftung, German Academic Exchange Service (DAAD).Kai M. Schmidt-Ott (KMSO) reports receiving research funding from Deutsche Forschungsgemeinschaft (CRC 1365, GRK 2318, RU 2841), Urological Research Foundation Berlin, ERA PerMed (OnAKI-ICI), COVID-19-Forschungsnetzwerk Niedersachsen (EXTINCT post COVID), Niedersächsisches Ministerium für Wissenschaft und Kultur (zukunft.Niedersachsen), FAST BioMedical, Quark Pharmaceuticals, REATA, Boehringer Ingelheim, AstraZeneca, Sanofi, Alentis, Roche, and Alexion; having received consultancy fees from BioPorto Diagnostics and Abionyx; having participated in advisory boards with Bayer, Stadapharm, and Boehringer Ingelheim; having received license revenue related to the use of a neutrophil gelatinase- associated lipocalin assay via Columbia University; and being an editorial board member of Kidney International and Kidney International Reports; each outside the submitted work.Jeanette Schulz-Menger (JSM) reports grants from Bayer Healthcare, non-financial support from Siemens healthineers, non-financial support from Circle cardiovascular, non-financial support from Medis, outside the submitted work, and Bayer Healthcare, Advisor. Furthermore, funding for research from the EU, DZHK, Deutsche Herzstiftung.Jochen Spranger (JS) received funding for research from Deutsche Forschungsgemeinschaft and from BMBF.Martin Witzenrath (MW) received funding for research from Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Deutsche Gesellschaft für Pneumologie, European Respiratory Society, Marie Curie Foundation, Else Kröner Fresenius Foundation, Capnetz Foundation, International Max Planck Research School, Actelion, Bayer Health Care, Biotest, Boehringer Ingelheim, Noxxon, Pantherna, Quark Pharma, Vaxxilon, and for lectures and advisory from Actelion, Aptarion, Astra Zeneca, Bayer Health Care, Berlin Chemie, Biotest, Boehringer Ingelheim, Chiesi, Glaxo Smith Kline, Novartis, Noxxon, Pantherna, Teva und Vaxxilon.All remaining authors do not report potential conflicts of interest.